



**FOR IMMEDIATE RELEASE**

**RPS Appoints Mark D. Myslinski Chief Executive Officer**

\* \* \* \* \*

SARASOTA, FL. (January 18, 2012) – Rapid Pathogen Screening, Inc. (RPS®) is pleased to announce the appointment of Mark D. Myslinski as Chief Executive Officer.

Myslinski brings nearly 30 years of successful leadership experience in life sciences and diagnostic companies ranging from Fortune 100 companies to small, venture-backed start up organizations. Before joining RPS, Myslinski has held positions as Senior Vice President and General Manager, Diagnostics of Hologic, Inc. Prior to that, Myslinski was President and CEO of RedPath Integrated Pathology, Inc. He has also successfully led Veridex LLC, a subsidiary of Johnson & Johnson’s Ortho-Clinical Diagnostics, as General Manager where the team pioneered the clinical use of circulating tumor cells.

“Mark brings a wealth of knowledge and valuable point of care diagnostic experience to RPS,” said Robert Sambursky MD, President, Chief Medical Officer, and Executive Chairman of RPS. “His diverse background and strong leadership skills will accelerate our growth as a leader in the development of novel and rapid in-office tests for infectious and inflammatory diseases.”

Myslinski stated, “I am thrilled to lead this team to further leverage the RPS platform to improve the speed and accuracy of diagnoses and, importantly, to drive down health care costs. The point-of-care market is growing rapidly and RPS has developed a first-of-its-kind platform that can disrupt some diagnostic algorithms, bringing more rapid and accurate results to the point of care. This innovative platform more quickly empowers health care providers with evidence to aid them in making informed treatment decisions.”

Myslinski earned his BA in Economics from Moravian College and his MBA from Ohio University. He is also an active member of the Board of Directors of two diagnostics companies.

**About RPS**

Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is a leading developer, manufacturer and marketer of rapid, easy-to-use, point-of-care diagnostic tests. The company’s revolutionary, patented Direct Sampling Micro-Filtration (DSMF) technology and patent-pending Direct Multi-Planar Chromafiltography (DMC) technology allow for the current and future development of tests to confirm patients with infectious diseases and agents, inflammatory conditions, and asymptomatic exposure to chemical warfare and bio-terrorism agents. RPS tests have superior sensitivity and specificity and can be easily performed by a clinician’s staff without extensive training or additional equipment.

###

**For additional information, contact:**

Laura Lovejoy, Manager of Business Development, RPS, 941.556.1864